文献速递神经肿瘤

无功能垂体神经内分泌肿瘤首程立体定向放射外科:国际多中心研究

Upfront Stereotactic Radiosurgery for Nonfunctioning Pituitary Neuroendocrine Tumors: An International, Multicenter Study.
PubMed 文献 · Neurosurgery · 2025-10-07

本研究评估未治疗的无功能垂体腺瘤患者接受单次立体定向放射外科(SRS)的肿瘤控制与并发症。132例患者中,3、5、8年肿瘤控制概率分别为100%、98.1%、92.4%;新发垂体功能减退累积概率逐年上升,无新发视野缺损。结论认为首程SRS对合适选择的患者有效安全,但视野改善率低,需谨慎选择患者并延长随访。

要点

  • 首程SRS对未治疗的无功能垂体腺瘤肿瘤控制率较高,8年达92.4%。
  • 新发垂体功能减退累积概率8年达29.5%,需长期监测内分泌功能。
  • 无新发视野缺损,但原有视野缺损完全改善率仅34.7%。

核心结论

  • 首程SRS对合适选择的未治疗无功能垂体腺瘤患者有效且安全,但需更长期随访。
  • 视野改善率低,需仔细选择患者。

研究设计与样本

  • 国际多中心队列研究,评估未治疗无功能垂体腺瘤患者接受单次SRS后的肿瘤控制和并发症。
  • 共纳入132例患者,SRS时中位年龄51.2岁(IQR 27.1),中位肿瘤体积2.1 cm³(IQR 2.9)。

主要发现

  • 肿瘤控制概率在SRS后3、5、8年分别为100%(95% CI 100-100)、98.1%(95% CI 94.6-100)、92.4%(95% CI 81.6-100)。
  • 新发垂体功能减退累积概率在3、5、8年分别为11.7%(95% CI 3.8-18.9)、24.4%(95% CI 12.1-35.1)、29.5%(95% CI 12.1-26.9)。
  • 无新发视野缺损;SRS前存在视野缺损的50例(37.9%)中,末次随访(中位2.2年,IQR 3.9)时完全改善17例(34.7%)、部分改善12例(24.5%)、稳定19例(38.8%)、加重1例(2.0%)。
  • SRS前存在动眼神经麻痹的10例(7.6%)中,1例(0.8%)出现新发暂时性神经麻痹;末次随访(中位2.5年,IQR 4.4)时稳定5例(45.4%)、部分改善1例(9.1%)、完全改善5例(45.4%)。

临床怎么用

  • 对于不适合手术的未治疗无功能垂体腺瘤,首程SRS可作为治疗选择。
  • 治疗前需评估视野和动眼神经功能,并向患者说明视野改善可能性较低。
  • SRS后需长期随访肿瘤控制、垂体功能及神经功能。

局限性

  • 随访时间仍较短,需要更长期随访。
  • 为多中心回顾性队列,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Upfront stereotactic radiosurgery (SRS) could be an option for nonfunctioning pituitary adenomas (NFPA) unsuitable for surgery. Only small series evaluate the results of upfront SRS; the aim of the study was to report patient outcomes from a large, international patient cohort. METHODS: The study evaluated tumor control and complications after single-session SRS in a multicentric cohort of untreated NFPA. RESULTS: In total, 132 patients (median age 51.2 [IQR: 27.1] years at SRS, median volume 2.1 [IQR: 2.9] cm 3 ) were included. The probability of tumor control was 100% (95% CI: 100-100), 98.1% (95% CI: 94.6-100), and 92.4 (95% CI: 81.6-100) at 3, 5, and 8 years after SRS. The cumulative probability of new pituitary deficit was 11.7% (95% CI: 3.8-18.9), 24.4% (95% CI: 12.1-35.1), and 29.5% (95% CI: 12.1-26.9) at 3, 5, and 8 years, respectively. No new visual field defect occurred. Before SRS, 50 patients (37.9%) presented with a visual field defect with a complete improvement in 17 (34.7%), partial improvement in 12 (24.5%), and stability in 19 (38.8%) at a last follow-up of 2.2 (3.9) years. One patient (2.0%) worsened after SRS. Before SRS, 10 patients (7.6%) presented with an oculomotor nerve palsy. One patient (0.8%) developed a new transient nerve palsy. At a last follow-up of 2.5 (4.4) years, 5 patients (45.4 35.7%) had a stability of their palsy, 1 had a partial improvement (9.1%), and 5 (45.4%) had a complete improvement. CONCLUSION: Upfront SRS represents an option for appropriately selected patients with NFPA, and it exhibits a favorable efficacy and safety profile, but a longer follow-up is required. Visual improvement is low, and careful selection of patient is required.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Dumot C, Mantziaris G, Dayawansa S, et al. Upfront Stereotactic Radiosurgery for Nonfunctioning Pituitary Neuroendocrine Tumors: An International, Multicenter Study. Neurosurgery. 2025. PMID: 41055356. doi:10.1227/neu.0000000000003799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。